MedTech Funding Mandate An NHS commitment to get selected NICE-approved cost-saving devices, diagnostics & digital products to patients more quickly. The MedTech Funding Mandate (MTFM) The policy supports devices, diagnostics or digital products that: are effective and improve patient outcomes: demonstrated through positive NICE guidance; are cost-saving within three years: NICE modelling demonstrates a net saving within three years of implementing the technology; are affordable to the NHS: the budget impact should not exceed £20 million, in any of the first three years. The policy defines a list of NICE-approved technologies that NHS commissioners and providers are mandated to agree local funding arrangements for through their existing allocations. This is to ensure healthcare providers across England enable equitable access to patients. The MTFM policy is an NHS England initiative, delivered with the support of the 15 health innovation networks who work closely with their local Integrated Care Systems (ICSs). Access policy guidance Apos Health Apos Health joined the MedTech Funding Mandate for national adoption for 2024/25. The Apos Health shoe is a NICE recommended medical device, clinically proven to reduce knee OA pain. Modelled savings indicate an average cost saving per patient per year of £1,478. Knee Osteoarthritis (KOA) is a major clinical and economic burden to the NHS, affecting approximately one in five adults (18.2%) over 45 years of age in England1. Total knee replacement (TKR) is considered an effective treatment for end-stage knee OA, but it is associated with risks, complications and long waiting lists. Download Apos Health one-pager Health Innovation KSS is the lead health innovation network coordinating the spread of Apos through England through all 15 networks across the country. Get in touch to find out more. 2022/23 technologies The technologies included in the MTFM 2022/23 policy are categorised into the following two themes: Benign prostatic hyperplasia (BPH) – a common condition in ageing men and others with a prostate (trans women, some non-binary and some intersex people). It is currently treated with the surgical procedure, transurethral resection of the prostate (TURP) which usually requires the patient to stay in hospital for 1 to 3 days. Four less invasive innovations allow patients with BPH to be treated as day cases. Four technologies are an alternative treatment to transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: Greenlight XPS – uses a laser to reduce the size of an enlarged prostate. Rezum – uses water vapour to destroy excess prostate tissue. PLASMA System – uses electrodes to cut out prostate tissue. UroLift – lifts and holds the enlarged prostate tissue away from the urethra, relieving the compression of this organ. Improving the patient experience during procedures – using technology can provide alternatives to otherwise more invasive and costly procedures. Three technologies are an alternative to more invasive procedures: Spectra Optia – apheresis and cell collection platform for people with sickle cell disease who require automated red cell exchange. XprESS Multi Sinus Dilation System – a sterile, single-use device for treating chronic sinusitis with a dilating balloon. Thopaz+ – a portable digital chest drain system which accurately monitors and records air leak and fluid drainage. 2021/22 technologies Placental growth factor based testing (PlGF) – a blood test to rule out pre-eclampsia in pregnant women. SecurAcath – for securing percutaneous catheters. HeartFlow – creates a 3D model of a patient’s coronary arteries and assesses the extent and location of blockages. gammaCore – a handheld device which alleviates the symptoms of severe cluster headaches. News and case studies AI visionaries leading health innovation for women: Call for nominations Health Innovation Kent Surrey Sussex (KSS) and the Department of Health and Social Care (DHSC) have today [30 October] launched... News 30 Oct 2024 More Health Innovation Kent Surrey Sussex CEO Appointed as AI and Innovation Professor at University of Surrey School of Medicine Professor Hatim Abdulhussein, CEO of Health Innovation KSS, has been appointed as Honorary Professor of Innovation and Artificial Intelligence (AI) at the University of Surrey's School of Medicine. News 11 Oct 2024 More BBC South Today – AI in Healthcare Our CEO, Prof Hatim Abdulhussein spoke to BBC South Today's Katharine Da Costa about AI in Healthcare. Video 14 Aug 2024 More Code Meets Care: Integration of AI and automation in General Practice Health Innovation KSS's recent roundtable on AI and automation in primary care explored what primary care needs from NHSE and ICBs (the system) and innovators to optimise the use of AI and automation. News 22 Jul 2024 More Breaking the silence: Clera Healthcare debuts its technology in a new pilot Clera Healthcare has completed its first pilot at Hobbs rehabilitation centre, which supports NHS and private patients affected by neurological conditions or injury. News 19 Jul 2024 More Independent evaluation finds Metadvice AI is an effective tool for reducing clinician workload in UK Primary Care Health Innovation Kent Surrey Sussex comissioned Unity Insights, facilitated by the Office of Life Sciences commission, to evaluate the application of the Metadvice artificial intelligence (AI) precision clinical guidance tool within the Ball Tree Surgery in Lancing and Sompting PCN. News 18 Jul 2024 More Health Innovation KSS partners with the Kent, Medway and Sussex Secure Data Environment for research Health Innovation KSS is a programme partner for the Kent, Medway and Sussex Secure Data Environment (KMS SDE) for research. News 17 Jun 2024 More CEO video diary – Episode 2 Hatim shares his highlights from attending the inaugural RAISE Health Symposium at Stanford University, bringing together experts from across industries to discuss AI in health care for thought-provoking panels and discussions. Video 30 May 2024 More Clera Healthcare: Created by clinical entrepreneurs to improve communication with patient families Jonathan Abeles and Alice Appleton are NHS doctors and Co-Founders of Clera Healthcare. Case Study 15 Apr 2024 More Evaluation finds that AI-enhanced patient triage could support primary care Visiba, a company supported by Health Innovation KSS, has published an evaluation assessing the impact of using AI-enabled patient triage in the operational delivery of primary care. News 11 Mar 2024 More How can we help reduce health inequalities through digital inclusion? Kath Sykes explores what the health and care system can do to help digitally include all parts of our population, to enable everyone that could benefit from digital health and care to do so, and reduce the risk of health inequalities as a result. BlogNews 8 Feb 2024 More Apos Health for Knee Osteoarthritis joins the MedTech Funding Mandate Health Innovation KSS has supported Apos Health since 2019 and it has now been announced that the company will be joining the MedTech Funding Mandate for national adoption for 2024/25. News 19 Jan 2024 More ← → Contact us If you’d like to find out more about the MedTech Funding Mandate or any the technologies, get in touch. Meet the team Get in touch